Bellerophon Therapeutics and Worldwide Clinical Trials Selected as Finalists in 2017 Care Awards
MORRISVILLE, North Carolina, March 7, 2017 /PRNewswire/ --
Worldwide Clinical Trials (http://www.worldwide.com) and Bellerophon Therapeutics (http://www.bellerophon.com) have been selected as finalists in the 2017 Clinical Research & Excellence (CARE) Awards in the "Clinical Partnership of the Year" category. This category recognizes collaborations between organizations whose clinical trial activity has set a new benchmark in partnering activity.
Partners in clinical research since 2010, Worldwide is currently supporting Bellerophon with its investigation into the INOpulse product candidate, a portable device that delivers inhaled nitric oxide to patients. Bellerophon recently announced that it received acceptance from the U.S. Food and Drug Administration (FDA) for modifications proposed to its Phase 3 program for INOpulse in pulmonary arterial hypertension. These protocol changes could potentially make INOpulse available approximately two years earlier than previously predicted, therefore reducing time to market and resulting in substantial clinical development cost savings for Bellerophon. Worldwide is providing a broad range of services for the INOpulse clinical development program, including regulatory affairs, site monitoring, project management, safety and medical monitoring support, and trial master file services.
Worldwide and Bellerophon are being recognized by the CARE Awards for the success of their long-time partnership. This partnership has evolved as a result of the two companies' realistic, solutions-oriented approach - including frequent review and reporting of metrics, open communication from every level of the organization, and accountability by leaders at both Bellerophon and Worldwide to quickly consider and resolve issues.
"Throughout our collaboration with Worldwide, we've been impressed with the company's hands-on, highly responsive approach. Worldwide also has demonstrated a unique level of openness and flexibility as we've developed our relationship, both operationally and financially, demonstrating a true commitment to risk sharing," said Jonathan Peacock, Chairman of Bellerophon Therapeutics.
"We are delighted that our partnership with Bellerophon has been recognized and shortlisted as a finalist for such a prestigious award," commented Peter Benton, president and COO of Worldwide Clinical Trials. "Bellerophon's collaborative spirit has improved our clinical research partnership, and helped to make Worldwide's team better and stronger. A partnership like ours - one that lifts the abilities of both partners - is worthy of celebration."
The CARE Awards program, a part of the Business Intelligence Division of Informa, recognizes excellence across the global clinical research enterprise. The winners of the 2017 CARE awards, which will be decided upon by a distinguished panel of industry experts, will be announced at an event in Boston, Mass., on April 5, 2017. For more information, visit http://www.ibiawards.com/careawards.
Connect on social:
- Tweet: @worldwidetrials and Bellerophon Therapeutics selected as finalists in CARE Awards
- Follow us on Twitter: @worldwidetrials
- Find us on LinkedIn: https://www.linkedin.com/company/worldwide-clinical-trials-inc-
About Bellerophon Therapeutics: Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first candidate is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials in 2016. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF); both of these products are in Phase 2 development. For more information, please visit http://www.bellerophon.com.
About Worldwide Clinical Trials:
Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world's leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit Worldwide.com.
Bellerophon Therapeutics Fabian Tenenbaum, Chief Executive Officer (908) 574-4819 LifeSci Advisors Bob Yedid, Managing Director (646) 597-6989 firstname.lastname@example.org Worldwide Clinical Trials LuJean Smith, VP, Global Marketing Communications (610) 329-2056 email@example.com
SOURCE Worldwide Clinical Trials